Striking activation of NALT and nasal passages lymphocytes induced by intranasal immunization with Cry1Ac protoxin

Scandinavian Journal of Immunology

Volumn 71, Issue 3, 2010, Pages 159-168

  Rodriguez Monroy, M A ^a   Moreno Fierros, L ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

CD69 ANTIGEN; CHOLERA TOXIN; CRY1AC TOXIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4; INTERLEUKIN 5;

ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ARTICLE; BACILLUS THURINGIENSIS; CD4+ CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; IMMUNOGENICITY; IMMUNOSTIMULATION; LYMPHOCYTE ACTIVATION; LYMPHOID TISSUE; MALE; MOUSE; NASAL ASSOCIATED LYMPHOID TISSUE; NONHUMAN; NOSE MUCOSA; PRIORITY JOURNAL;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; B-LYMPHOCYTES; BACTERIAL PROTEINS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; ENDOTOXINS; HEMOLYSIN PROTEINS; IMMUNOGLOBULIN A; IMMUNOGLOBULINS; IMMUNOTHERAPY, ACTIVE; INTERLEUKIN-10; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; INTERLEUKIN-4; INTERLEUKIN-5; LECTINS, C-TYPE; LYMPHOCYTE ACTIVATION; LYMPHOID TISSUE; MALE; MICE; NASAL CAVITY; TH2 CELLS;

EID: 77449161040     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2009.02358.x     Document Type: Article

References (51)

1. Kuper CF, Koornstra PJ, Hameleers DM et al. The role of nasopharyngeal lymphoid tissue. Immunol Today 1992 13 : 219 224.
2. Bergquist C, Johansson EL, Lagergard T, Holmgren J, Rudin A. Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and the vagina. Infect Immun 1997 65 : 2676 2684.
3. Zuercher AW. Upper respiratory tract immunity. Viral Immunol 2003 16 : 279 289.
4. Bienenstock J, McDermott MR. Bronchus- and nasal-associated lymphoid tissues. Immunol Rev 2005 206 : 22 31.
5. Hiroi T, Iwatani K, Iijima H, Kodama S, Yanagita M, Kiyono H. Nasal immune system: distinctive Th0 and Th1/Th2 type environments in murine nasal-associated lymphoid tissues and nasal passage, respectively. Eur J Immunol 1998 28 : 3346 3353.
6. Hirano T, Jiao X, Chen Z, Van Waes C, Gu XX. Kinetics of mouse antibody and lymphocyte responses during intranasal vaccination with a lipooligosaccharide-based conjugate vaccine. Immunol Lett 2006 15 : 107.
7. Liang B, Hyland L, Hou S. Nasal-associated lymphoid tissue is a site of long-term virus-specific antibody production following respiratory virus infection of mice. J Virol 2001 75 : 5416 5420.
8. Rodriguez-Monroy MA, Rojas-Hernandez S, Moreno-Fierros L. Phenotypic and functional differences between lymphocytes from NALT and nasal passages of mice. Scand J Immunol 2007 65 : 276 288.
9. Moreno-Fierros L, Garcia N, Gutierrez R, Lopez-Revilla R, Vazquez-Padron RI. Intranasal, rectal and intraperitoneal immunization with protoxin Cry1Ac from Bacillus thuringiensis induces compartmentalized serum, intestinal, vaginal and pulmonary immune responses in Balb/c mice. Microbes Infect 2000 2 : 885 890.
10. Moreno-Fierros L, Ruiz-Medina EJ, Esquivel R, Lopez-Revilla R, Pina-Cruz S. Intranasal Cry1Ac protoxin is an effective mucosal and systemic carrier and adjuvant of Streptococcus pneumoniae polysaccharides in mice. Scand J Immunol 2003 57 : 45 55.
11. Vazquez RI, Moreno-Fierros L, Neri-Bazan L, De La Riva GA, Lopez-Revilla R. Bacillus thuringiensis Cry1Ac protoxin is a potent systemic and mucosal adjuvant. Scand J Immunol 1999 49 : 578 584.
12. Vazquez-Padron RI, Moreno-Fierros L, Neri-Bazan L, De la Riva GA, Lopez-Revilla R. Intragastric and intraperitoneal administration of Cry1Ac protoxin from Bacillus thuringiensis induces systemic and mucosal antibody responses in mice. Life Sci 1999 64 : 1897 1912.
13. Vazquez-Padron RI, Moreno-Fierros L, Neri-Bazan L, Martinez-Gil AF, de-la-Riva GA, Lopez-Revilla R. Characterization of the mucosal and systemic immune response induced by Cry1Ac protein from Bacillus thuringiensis HD 73 in mice. Braz J Med Biol Res 2000 33 : 147 155.
14. Rojas-Hernandez S, Rodriguez-Monroy MA, Lopez-Revilla R, Resendiz-Albor AA, Moreno-Fierros L. Intranasal coadministration of the Cry1Ac protoxin with amoebal lysates increases protection against Naegleria fowleri meningoencephalitis. Infect Immun 2004 72 : 4368 4375.
15. Ge AZ, Pfister RM, Dean DH. Hyperexpression of a Bacillus thuringiensis delta-endotoxin-encoding gene in Escherichia coli: properties of the product. Gene 1990 1 : 93.
16. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976 7 : 72.
17. Lycke N, Karlsson U, Sjolander A, Magnusson KE. The adjuvant action of cholera toxin is associated with an increased intestinal permeability for luminal antigens. Scand J Immunol 1991 33 : 691 698.
18. Wu HY, Nikolova EB, Beagley KW, Russell MW. Induction of antibody-secreting cells and T-helper and memory cells in murine nasal lymphoid tissue. Immunology 1996 88 : 493 500.
19. Wu HY, Nguyen HH, Russell MW. Nasal lymphoid tissue (NALT) as a mucosal immune inductive site. Scand J Immunol 1997 46 : 506 513.
20. Hiroi T, Goto H, Someya K et al. HIV mucosal vaccine: nasal immunization with rBCG-V3J1 induces a long term V3J1 peptide-specific neutralizing immunity in Th1- and Th2-deficient conditions. J Immunol 2001 15 : 167.
21. Matsuo K, Yoshikawa T, Asanuma H et al. Induction of innate immunity by nasal influenza vaccine administered in combination with an adjuvant (cholera toxin). Vaccine 2000 1 : 18.
22. Yanagita M, Hiroi T, Kitagaki N et al. Nasopharyngeal-associated lymphoreticular tissue (NALT) immunity: fimbriae-specific Th1 and Th2 cell-regulated IgA responses for the inhibition of bacterial attachment to epithelial cells and subsequent inflammatory cytokine production. J Immunol 1999 15 : 162.
23. Hagiwara Y, McGhee JR, Fujihashi K et al. Protective mucosal immunity in aging is associated with functional CD4+ T cells in nasopharyngeal-associated lymphoreticular tissue. J Immunol 2003 15 : 170.
24. Kurono Y, Yamamoto M, Fujihashi K et al. Nasal immunization induces Haemophilus influenzae-specific Th1 and Th2 responses with mucosal IgA and systemic IgG antibodies for protective immunity. J Infect Dis 1999 180 : 122 132.
25. Asanuma H, Aizawa C, Kurata T, Tamura S. IgA antibody-forming cell responses in the nasal-associated lymphoid tissue of mice vaccinated by intranasal, intravenous and/or subcutaneous administration. Vaccine 1998 16 : 1257 1262.
26. Asanuma H, Hirokawa K, Uchiyama M et al. Immune responses and protection in different strains of aged mice immunized intranasally with an adjuvant-combined influenza vaccine. Vaccine 2001 16 : 19.
27. Heritage PL, Underdown BJ, Arsenault AL, Snider DP, McDermott MR. Comparison of murine nasal-associated lymphoid tissue and Peyer's patches. Am J Respir Crit Care Med 1997 156 : 1256 1262.
28. Watanabe I, Hagiwara Y, Kadowaki SE et al. Characterization of protective immune responses induced by nasal influenza vaccine containing mutant cholera toxin as a safe adjuvant (CT112K). Vaccine 2002 4 : 20.
29. Hiroi T, Yanagita M, Iijima H et al. Deficiency of IL-5 receptor alpha-chain selectively influences the development of the common mucosal immune system independent IgA-producing B-1 cell in mucosa-associated tissues. J Immunol 1999 15 : 162.
30. Baba TW, Liska V, Hofmann-Lehmann R et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 2000 6 : 200 206.
31. Mascola JR, Frankel SS, Broliden K. HIV-1 entry at the mucosal surface: role of antibodies in protection. AIDS 2000 14 (Suppl. 3 S167 74.
32. Robert-Guroff M. IgG surfaces as an important component in mucosal protection. Nat Med 2000 6 : 129 130.
33. Yoshida M, Claypool SM, Wagner JS et al. Human neonatal Fc receptor mediates transport of IgG into luminal secretions for delivery of antigens to mucosal dendritic cells. Immunity 2004 20 : 769 783.
34. Hogan RJ, Usherwood EJ, Zhong W et al. Activated antigen-specific CD8+ T cells persist in the lungs following recovery from respiratory virus infections. J Immunol 2001 1 : 166.
35. Hogan RJ, Zhong W, Usherwood EJ, Cookenham T, Roberts AD, Woodland DL. Protection from respiratory virus infections can be mediated by antigen-specific CD4(+) T cells that persist in the lungs. J Exp Med 2001 16 : 193.
36. Wiley JA, Hogan RJ, Woodland DL, Harmsen AG. Antigen-specific CD8(+) T cells persist in the upper respiratory tract following influenza virus infection. J Immunol 2001 15 : 167.
37. Kiyono H, Fukuyama S. NALT- versus Peyer's-patch-mediated mucosal immunity. Nat Rev Immunol 2004 4 : 699 710.
38. Lavelle EC. Generation of improved mucosal vaccines by induction of innate immunity. Cell Mol Life Sci 2005 62 : 2750 2770.
39. Moreno-Fierros L, Perez-Ordonez I, Palomar-Morales M. Slight influence of the estrous cycle stage on the mucosal and systemic specific antibody response induced after vaginal and intraperitoneal immunization with protoxin Cry1Ac from Bacillus thuringiensis in mice. Life Sci 2002 18 : 71.
40. Ryan EJ, Daly LM, Mills KH. Immunomodulators and delivery systems for vaccination by mucosal routes. Trends Biotechnol 2001 19 : 293 304.
41. Ryan EJ, McNeela E, Murphy GA et al. Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells. Infect Immun 1999 67 : 6270 6280.
42. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999 14 : 401.
43. Clements JD, Hartzog NM, Lyon FL. Adjuvant activity of Escherichia coli heat-labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigens. Vaccine 1988 6 : 269 277.
44. Elson CO, Ealding W. Cholera toxin feeding did not induce oral tolerance in mice and abrogated oral tolerance to an unrelated protein antigen. J Immunol 1984 133 : 2892 2897. (Pubitemid 15216478)
45. Douce G, Giuliani MM, Giannelli V, Pizza MG, Rappuoli R, Dougan G. Mucosal immunogenicity of genetically detoxified derivatives of heat labile toxin from Escherichia coli. Vaccine 1998 16 : 1065 1073.
46. Heritage PL, Brook MA, Underdown BJ, McDermott MR. Intranasal immunization with polymer-grafted microparticles activates the nasal-associated lymphoid tissue and draining lymph nodes. Immunology 1998 93 : 249 256.
47. Shimoda M, Nakamura T, Takahashi Y et al. Isotype-specific selection of high affinity memory B cells in nasal-associated lymphoid tissue. J Exp Med 2001 3 : 194.
48. Bowen JC, Nair SK, Reddy R, Rouse BT. Cholera toxin acts as a potent adjuvant for the induction of cytotoxic T-lymphocyte responses with non-replicating antigens. Immunology 1994 81 : 338 342.
49. Porgador A, Staats HF, Faiola B, Gilboa E, Palker TJ. Intranasal immunization with CTL epitope peptides from HIV-1 or ovalbumin and the mucosal adjuvant cholera toxin induces peptide-specific CTLs and protection against tumor development in vivo. J Immunol 1997 15 : 158.
50. Simmons CP, Mastroeni P, Fowler R et al. MHC class I-restricted cytotoxic lymphocyte responses induced by enterotoxin-based mucosal adjuvants. J Immunol 1999 15 : 163.
51. Guerrero GG, Russell WM, Moreno-Fierros L. Analysis of the cellular immune response induced by Bacillus thuringiensis Cry1A toxins in mice: effect of the hydrophobic motif from diphtheria toxin. Mol Immunol 2007 44 : 1209 1217.